However also the results of the studies performed in EGFR wild-type (WT) patients are controversial [29, 30], suggesting a potential survival benefit in favor of chemotherapy [31], but highlighting the urgent need of direct comparisons between TKI and chemotherapy in this setting of NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.